|
Cost-Effectiveness of Alendronate and Risedronate for Primary Prevention of Fractures in Postmenopausal Women |
|---|---|
| รหัสดีโอไอ | |
| Creator | Surasak Chaiyasong |
| Title | Cost-Effectiveness of Alendronate and Risedronate for Primary Prevention of Fractures in Postmenopausal Women |
| Contributor | Thananan Rattanachotphanit, On-anong Waleekhachonloet, Bunyat Sitthithanyakit |
| Publisher | Faculty of Pharmaceutical Sciences KKU MSU UBU |
| Publication Year | 2556 |
| Journal Title | Isan Journal ofPharmaceutical Sciences |
| Journal Vol. | 9 |
| Journal No. | 2 |
| Page no. | 23-36 |
| Keyword | Cost-effectiveness, Bisphosphonates, Osteoporosis, Fractures, Postmenopausal women. |
| URL Website | https://tci-thaijo.org/index.php/IJPS |
| Website title | Isan Journal ofPharmaceutical Sciences, IJPS |
| ISSN | 19050852 |
| Abstract | Introduction: This study determined the cost-effectiveness of generic-priced Alendronate and original-priced Risedronate for the primary prevention of fractures in postmenopausal women from the healthcare provider perspective. Epidemiological, clinical efficacy, cost and utility data were obtained from literature review. Method: A Markov model with nine health states was applied to estimate total costs and effectiveness for eight age-groups (45, 50, 55, 60, 65, 70, 75 and 80 years and above) using a 10-year time horizon, 5-year duration of medication, 50% medication adherence and a linear reduction of residual effect of the medicines. One-way and probabilistic sensitivity analyses were conducted. Results: Incremental cost-effectiveness ratios (ICER) of Alendronate and Risedronate were higher than three times of Gross Domestic Product (GDP) per capita, ranging from 801,353 7,012,743 Baht/quality-adjusted life year (QALY) gained and 1,727,023 13,967,461 Baht/QALY gained respectively. If the prices of generic Alendronate and original Risedronate decreased by 60% and 80% respectively, these drugs would be cost-effective for those aged 75 years and older. In conclusion, the use of Alendronate and Risedronate for the primary prevention of fractures is not cost-effective for all age-groups of postmenopausal women. Cost-effectiveness analysis of these drugs for the secondary prevention should be further conducted. |
